Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editor for this issue.
Petri T. Kovanen
Dr Kovanen received his medical degree in 1970 from the University of Basle, Switzerland, and his M.D. Ph.D degree in 1975 from the University of Helsinki, Finland. He conducted postdoctoral work (1976 – 1980) with Nobel Laureates Joseph L. Goldstein and Michael S. Brown in the Departments of Molecular Genetics and Internal Medicine at the University of Texas, Health Science Center at Dallas, USA. After his return to Finland, he completed his residency in Internal Medicine at the University of Helsinki (head, the late Professor Esko Nikkilä). In 1984 he was appointed Scientific Director of Wihuri Research Institute, Helsinki, and currently serves as Director of the Institute.
His main research interests focus on the pathogenesis of atherosclerosis, both on early atherogenesis with emphasis on the mechanisms of extracellular lipid accumulation, and on late atherogenesis with emphasis on the generation of vulnerable plaques. He has been exploring the role of mast cells, rediscovered invaders of the atherosclerotic arterial intima, in atherogenesis and its clinical complications. Dr Kovanen has published numerous scientific articles, reviews, and book chapters on topics dealing with the pathophysiology of atherosclerosis, particularly on proteolytic and lipolytic modifications of LDL and HDL. The leading theme of his work has been exploration of the roles of mast cells as potent effector cells in atherogenesis.
Dr Kovanen has served as Editor-in-Chief of Annals of Medicine, and as Editorial Board Member of Arteriosclerosis, Thrombosis, and Vascular Biology. He has also served as a Council Member of the Scandinavian Society for Atherosclerosis Research and Councillor of the European Vascular Biology Organization. He is past President of the Finnish Atherosclerosis Society, and is currently Secretary of the European Atherosclerosis Society, and also chairs its Scientific Committee.
Andrew Newby is British Heart Foundation Professor of Vascular Cell Biology. He graduated in Natural Sciences (Biochemistry) from Cambridge and studied for a PhD with Professor CN Hales FRS. He then worked on adenylate cyclase with Nobel Laureate Martin Rodbell at the NIH in Bethesda, Maryland. Afterwards, he held a Beit Memorial Fellowship in Cambridge where he elucidated the metabolic pathways responsible for production of the cardioprotective metabolite, adenosine. Subsequently, he was successively Non-clinical Lecturer, Senior Lecturer, Reader and Professor in Cardiff. While continuing to work on adenosine, he contributed to the identification of the endothelium-derived relaxing factor as nitric oxide. He is most know however, for discovering a role for matrix degrading metalloproteinases in vascular smooth muscle cell migration and proliferation in vein grafts, after angioplasty and in atherosclerosis. His elucidation of the inflammatory basis of metalloproteinase production is continuing to shed light on the role of inflammation in plaque rupture and myocardial infarction. He was one of the first vascular biologists to use of adenovirus-mediated gene transfer which he now combines with other post-genome technologies. This work has led to more than 150 peer-reviewed research papers and 30 reviews, which have collectively attracted 8000 citations (H>57). It was continuously supported by UK programme grants for the past 20 years. Prof. Newby was also Co-director of the EC-funded European Vascular Genomics Network.
Prof. Newby has served on grants committees of the major UK Research Councils and Charities and also reviewed grants for Belgian, Dutch, French, German and other overseas bodies. His Editorial Boards include Atherosclerosis, ATVB and Cardiovascular Research.
Prof. Newby has been an EAS member for many years and recently served on the Programme Committee for the Helsinki and Gothenburg congresses. He has more than 20 years involvement with the European Society of Cardiology, being a founder member and later Chair of the working group Pathogenesis of Atherosclerosis, a member of the Congress Programme Committee and Chairman of the Council on Basic Cardiovascular Science. He now dedicates himself to running the biennial ESC Summer Schools in Cardiovascular Biology. Perhaps most significantly he re-launched and was President of the European Vascular Biology Organisation from 2006 to 2010.